In a breakthrough study published in the Journal of Clinical Investigation, researchers from the University of Michigan and the University…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
Researchers from the University of Michigan and the University of California San Diego have published a groundbreaking study identifying the…
Read More
Merck KGaA and Remepy Forge Groundbreaking Partnership to Pioneer "Hybrid Drugs" for Rare Cancers
In a move that signals a significant shift in pharmaceutical innovation, Merck KGaA has announced a strategic collaboration with Remepy,…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
This fundamental discovery, detailed in a collaborative study by researchers from the University of Michigan and the University of California…
Read More
Boehringer Ingelheim and Zai Lab Forge Clinical Collaboration to Pioneer Novel Combination Therapy for Aggressive Lung Cancers
Boehringer Ingelheim and Zai Lab have announced a significant clinical collaboration aimed at investigating a dual delta-like ligand 3 (DLL3)-targeting…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The phenomenon of cancer recurrence remains one of the most significant challenges in modern oncology, particularly in the context of…
Read MoreYOU MAY HAVE MISSED
